IL324897A - Trem2 agonists - Google Patents

Trem2 agonists

Info

Publication number
IL324897A
IL324897A IL324897A IL32489725A IL324897A IL 324897 A IL324897 A IL 324897A IL 324897 A IL324897 A IL 324897A IL 32489725 A IL32489725 A IL 32489725A IL 324897 A IL324897 A IL 324897A
Authority
IL
Israel
Prior art keywords
dimethyl
chloro
phenyl
tetrahydropyran
fluoro
Prior art date
Application number
IL324897A
Other languages
English (en)
Hebrew (he)
Inventor
Stefan Berchtold
Virginie Sacha Brom
Julie Charpentier
Francesco Maria Emilia Di
Guido Galley
Luca Claudio Gobbi
Wolfgang Guba
Roland Johann Humm
Marie-Paule Imhoff
Fionn Susannah O'hara
Ang?Lique Patiny-Adam
Flore Marie Aude Reggiani
Nicolas Zeidan
Original Assignee
Hoffmann La Roche
Stefan Berchtold
Virginie Sacha Brom
Julie Charpentier
Francesco Maria Emilia Di
Guido Galley
Luca Claudio Gobbi
Wolfgang Guba
Roland Johann Humm
Imhoff Marie Paule
Ohara Fionn Susannah
Patiny Adam Ang?Lique
Flore Marie Aude Reggiani
Nicolas Zeidan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Stefan Berchtold, Virginie Sacha Brom, Julie Charpentier, Francesco Maria Emilia Di, Guido Galley, Luca Claudio Gobbi, Wolfgang Guba, Roland Johann Humm, Imhoff Marie Paule, Ohara Fionn Susannah, Patiny Adam Ang?Lique, Flore Marie Aude Reggiani, Nicolas Zeidan filed Critical Hoffmann La Roche
Publication of IL324897A publication Critical patent/IL324897A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL324897A 2023-06-19 2024-06-17 Trem2 agonists IL324897A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP23179957 2023-06-19
EP23211237 2023-11-21
PCT/EP2024/066833 WO2024260929A1 (en) 2023-06-19 2024-06-17 Trem2 agonists

Publications (1)

Publication Number Publication Date
IL324897A true IL324897A (en) 2026-01-01

Family

ID=91621082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324897A IL324897A (en) 2023-06-19 2024-06-17 Trem2 agonists

Country Status (14)

Country Link
EP (1) EP4727934A1 (es)
JP (1) JP2026521750A (es)
KR (1) KR20260023587A (es)
CN (1) CN121335893A (es)
AR (1) AR132992A1 (es)
AU (1) AU2024312352A1 (es)
CL (1) CL2025004002A1 (es)
CO (1) CO2025018165A2 (es)
CR (1) CR20250537A (es)
IL (1) IL324897A (es)
MX (1) MX2025015264A (es)
PE (1) PE20260310A1 (es)
TW (1) TW202515878A (es)
WO (1) WO2024260929A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2025206254A1 (en) 2024-01-04 2026-06-11 Muna Therapeutics Aps Trem2 modulators
IL328677A (en) 2024-01-04 2026-07-01 Muna Therapeutics Aps 2-Azatidinyl-7-methyl-8-oxo-6-(trifluoromethyl)-8,7-dihydropyrimido[4,5-D]pyrimidine derivatives as TREM2 modulators for the treatment of neurodegenerative diseases
WO2026077861A1 (en) * 2024-10-07 2026-04-16 F. Hoffmann-La Roche Ag Trem2 agonists
WO2026115009A1 (en) * 2024-11-29 2026-06-04 F. Hoffmann-La Roche Ag Trem2 agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318732B2 (en) * 2008-07-02 2012-11-27 Avexa Limited Compounds having antiviral properties
EP4430029A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE

Also Published As

Publication number Publication date
CL2025004002A1 (es) 2026-04-06
WO2024260929A1 (en) 2024-12-26
CO2025018165A2 (es) 2026-01-23
EP4727934A1 (en) 2026-04-22
MX2025015264A (es) 2026-02-03
TW202515878A (zh) 2025-04-16
JP2026521750A (ja) 2026-07-01
AU2024312352A1 (en) 2025-12-11
PE20260310A1 (es) 2026-02-11
AR132992A1 (es) 2025-08-13
CN121335893A (zh) 2026-01-13
CR20250537A (es) 2026-01-19
KR20260023587A (ko) 2026-02-20

Similar Documents

Publication Publication Date Title
US11472794B2 (en) Fused imidazole derivatives as IL-17 modulators
CA3182105A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2024260929A1 (en) Trem2 agonists
JP2024519496A (ja) ブルトンのチロシンキナーゼの分解を標的化するための化合物
TW202309029A (zh) 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
JP7669299B2 (ja) 複素環モノアシルグリセロールリパーゼ(magl)阻害剤
CA3215260A1 (en) Heterocyclic compounds
JP2019089828A (ja) オータキシン阻害剤としての新規オクタヒドロ−ピロロ[3,4−c]−ピロール誘導体及びそのアナログ
CA2947338A1 (en) Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor
JP2025540958A (ja) 蕁麻疹の治療のための野生型c-kitキナーゼ阻害剤としてのN-フェニル-ピラゾロ[1,5-A]ピリジン-3-カルボキサミド誘導体
JP2023510874A (ja) 置換ピラゾロ-ピリミジンおよびその使用
WO2024246018A1 (en) Trem2 agonists
WO2024246019A1 (en) Pyrido[3,4-d]pyrimidin-4-one and pyrimido[5,4-d]pyrimidin-4-one derivatives as trem2 agonists for the treatment of parkinson's disease
WO2025176748A1 (en) Condensed pyrazines or pyrimidines als trem2 agoonists
WO2023239846A1 (en) Heterocyclic compounds as pi3kα inhibitors
JP2025503438A (ja) モノアシルグリセロールリパーゼ阻害剤として有用な二環式複素環化合物
WO2026077862A1 (en) Trem2 agonists
WO2026077861A1 (en) Trem2 agonists
WO2025176753A1 (en) Condensed pyrimidine derivates als trem2 agonists
HK40129411A (en) Pyrido[3,4-d]pyrimidin-4-one and pyrimido[5,4-d]pyrimidin-4-one derivatives as trem2 agonists for the treatment of parkinson's disease
WO2026087634A1 (en) Trem2 agonists
TW202615031A (zh) 作為可溶性環氧化物水解酶抑制劑之吡啶酮甲醯胺衍生型化合物
WO2025125135A1 (en) Spiropiperidine urea-derived compounds as soluble epoxide hydrolase inhibitors
EA051229B1 (ru) Гетероциклические соединения